AB Corporate Bond ETF (NASDAQ:EYEG) Sees Large Growth in Short Interest

AB Corporate Bond ETF (NASDAQ:EYEG – Get Free Report) saw a large increase in short interest in July. As of July 31st, there was short interest totaling 655 shares, an increase of 568.4% from the July 15th total of 98 shares. Based on an average trading volume of 295 shares, the short-interest ratio is presently 2.2 days. Approximately 0.0% of the shares of the stock are short sold.

AB Corporate Bond ETF Trading Up 0.3%

EYEG opened at $34.66 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.07 and a quick ratio of 3.07. The company’s 50 day simple moving average is $34.95 and its two-hundred day simple moving average is $35.28. AB Corporate Bond ETF has a 1-year low of $34.46 and a 1-year high of $36.63. The firm has a market capitalization of $27.73 million, a price-to-earnings ratio of -20.63 and a beta of 0.18.

Get AB Corporate Bond ETF alerts:

AB Corporate Bond ETF Increases Dividend

The business also recently disclosed a monthly dividend, which was paid on Thursday, August 6th. Investors of record on Monday, August 3rd were given a dividend of $0.1427 per share. The ex-dividend date was Monday, August 3rd. This is a positive change from AB Corporate Bond ETF’s previous monthly dividend of $0.14. This represents a c) dividend on an annualized basis and a yield of 4.9%. AB Corporate Bond ETF’s dividend payout ratio (DPR) is -102.38%.

Institutional Trading of AB Corporate Bond ETF

An institutional investor recently bought a new stake in AB Corporate Bond ETF stock. Kestra Advisory Services LLC purchased a new stake in shares of AB Corporate Bond ETF (NASDAQ:EYEG – Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 951 shares of the specialty pharmaceutical company’s stock, valued at approximately $34,000. Kestra Advisory Services LLC owned about 0.13% of AB Corporate Bond ETF at the end of the most recent quarter. 64.16% of the stock is currently owned by institutional investors.

AB Corporate Bond ETF Company Profile

(Get Free Report)

EyeGate Pharmaceuticals, Inc is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.

Featured Stories

• Five stocks we like better than AB Corporate Bond ETF
• Asian Market Circuit Breakers Hit Stocks, Not AI Demand
• Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
• Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
• Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal

Receive News & Ratings for AB Corporate Bond ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AB Corporate Bond ETF and related companies with MarketBeat.com's FREE daily email newsletter.